Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 HIV DNA prime and recombinant Tiantan vaccinia boost vaccine study
ChiCTR-PRC-12002493Phase 2Completed
- Sponsor
- CNAIDS
- Start
- Jul 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of recombinant Tiantan vaccinia vector vaccine in human immunodeficiency virus infection (HIV) (5 arms), sponsored by CNAIDS. Primary endpoints: Hematology, Liver and kidney function tests and 7 more. Started Jul 2012; status: completed.
02
Drugs
recombinant Tiantan vaccinia vector vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR-PRC-12002493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRC-12002493.